Dual PET/CT Imaging in Lung Cancer (DILUCE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01539928 |
Recruitment Status
: Unknown
Verified June 2013 by Mie Holm Vilstrup, Odense University Hospital.
Recruitment status was: Recruiting
First Posted
: February 28, 2012
Last Update Posted
: June 25, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Lung Cancer | Other: Dual FDG-PET/CT |
The investigators also want to:
- To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up (se Gold Standard 6.1.1)
- To compare SUVmax with the expression of GLUT1 and G-6-Pase in tumors
- To compare the expression of GLUT1 with the activity of G6Pase
- To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery
Study Type : | Observational |
Estimated Enrollment : | 216 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Dual PET/CT Imaging in Lung Cancer (Danish Title: En og Tre Timers FDG-PET/CT Ved Lungecancer) |
Study Start Date : | March 2012 |
Estimated Primary Completion Date : | March 2014 |
Estimated Study Completion Date : | March 2015 |

Group/Cohort | Intervention/treatment |
---|---|
lung cancer or high suspicion of lung cancer
After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
|
Other: Dual FDG-PET/CT
Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
|
- Sensitivity, specificity and accuracy [ Time Frame: After staging or 1 year of follow up ]To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up
- Occurence of relapse [ Time Frame: 1 year follow up after surgery ]• To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Cytologic/histologic-verified lung cancer or high suspicion of lung cancer after initial work up
- Candidate to curative intended surgery after initial work up (usually chest x-ray, CT of chest/upper abdomen and if needed spirometry).
Exclusion Criteria:
- Former lung cancer
- Contraindications for PET/CT: Pregnancy, recent chemoradiotherapy
- Diabetes mellitus.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01539928
Contact: Mie H Vilstrup, MD, Principal investigor | +45 2159 3008 | mie.holm.vilstrup@rsyd.dk | |
Contact: Poul Flemming Høilund-Carlsen, MD, DMSc, Professor | +45 3016 1445 | pfhc@rsyd.dk |
Denmark | |
Department of Pulmonary Medicine | Recruiting |
Odense C, Fünen, Denmark, 5000 | |
Contact: Niels Christian Hansen, MD niels.christian.hansen@rsyd.dk |
Principal Investigator: | Mie H Vilstrup, MD | Odense University Hospital |
Responsible Party: | Mie Holm Vilstrup, Principal investigator, MD, Odense University Hospital |
ClinicalTrials.gov Identifier: | NCT01539928 History of Changes |
Other Study ID Numbers: |
NMA 61 DILUCE |
First Posted: | February 28, 2012 Key Record Dates |
Last Update Posted: | June 25, 2013 |
Last Verified: | June 2013 |
Keywords provided by Mie Holm Vilstrup, Odense University Hospital:
Dual time PET/CT glucose-6-phosphatase |
Additional relevant MeSH terms:
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |